See every side of every news story
Get Started
SubscribeLogin
optometrytimes.com image

News from optometrytimes.com

Top optometrytimes.com News

FDA Approves Once-Daily Vizz for Presbyopia
United States · United States

FDA Approves Once-Daily Vizz for Presbyopia

100% Center coverage: 1 sources
The FDA approved Vizz for the treatment of presbyopia in adults, according to a press release from Lenz Therapeutics.Once-daily Vizz (aceclidine ophthalmic solution 1.44%) contracts the iris sphincter muscle, creating a pinhole effect to extend depth of focus and improve near vision without a myopic shift, according to the release.See the Story
Exonate Plans 'CLEAR-DE' Phase IIb Clinical Trial of Lead Candidate EXN407 for Diabetic Eye Disease

Exonate Plans 'CLEAR-DE' Phase IIb Clinical Trial of Lead Candidate EXN407 for Diabetic Eye Disease

100% Center coverage: 1 sources
Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, today announced plans to initiate a Phase IIb clinical trial for its lead candidate EXN407.See the Story
Enrolment Concludes in EyePoint’s Phase III Programme of Duravyu for Wet AMD
AMD · Lugano

Enrolment Concludes in EyePoint’s Phase III Programme of Duravyu for Wet AMD

EyePoint Pharmaceuticals has concluded subject enrolment in the pivotal Phase III programme assessing Duravyu, aimed at treating wet AMD.The post Enrolment concludes in EyePoint’s Phase III programme of Duravyu for wet AMD appeared first on Clinical Trials Arena.See the Story

Breaking News Topics Related to optometrytimes.com

AMD icon

AMD

Maryland icon

Maryland

Artificial Intelligence icon

Artificial Intelligence

United States icon

United States

News
For You
SearchBlindspotLocal